Corrigendum to “Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study” Eur Urol 83 (2023) 15–26, (S0302283822025544), (10.1016/j.eururo.2022.08.005)

Yu E.Y.; Piulats J.M.; Gravis G.Fong P.C.C.Todenhofer T.Laguerre B.Arranz J.A.Oudard S.Massard C.Heinzelbecker J.Nordquist L.T.Carles J.Kolinsky M.P.Augustin M.Gurney H.Tafreshi A.Li X.T.Qiu P.Poehlein C.H.Schloss C.de Bono J.S.

首页> 外文期刊>European urology >Corrigendum to “Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study” Eur Urol 83 (2023) 15–26, (S0302283822025544), (10.1016/j.eururo.2022.08.005)

【24h】

Corrigendum to “Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study” Eur Urol 83 (2023) 15–26, (S0302283822025544), (10.1016/j.eururo.2022.08.005)

机译：“帕博利珠单抗联合奥拉帕尼治疗转移性去势抵抗性前列腺癌患者：1b/2 期 KEYNOTE-365 队列 A 研究的长期结果”的更正 Eur Urol 83 （2023） 15–26，（S0302283822025544），（10.1016/j.eururo.2022.08.005）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

? 2022The authors regret that there was an error in the supplementary files – Table 6. The correct values for ‘Severe skin reaction’ are shown below, and also updated online accordingly. [Table presented]The authors would like to apologise for any inconvenience caused.

机译：?2022年作者对补充文件中存在错误感到遗憾——表6。“严重皮肤反应”的正确值如下所示，并相应地在线更新。[表格]对于给您带来的不便，作者深表歉意。

著录项

来源
《European urology》 |2023年第3期|共8页
作者
Yu E.Y.; Piulats J.M.; Gravis G.Fong P.C.C.Todenhofer T.Laguerre B.Arranz J.A.Oudard S.Massard C.Heinzelbecker J.Nordquist L.T.Carles J.Kolinsky M.P.Augustin M.Gurney H.Tafreshi A.Li X.T.Qiu P.Poehlein C.H.Schloss C.de Bono J.S.;
展开▼
作者单位

University of Washington and Fred Hutchinson Cancer Center;

Catalan Institute of Oncology;

Institut Paoli CalmettesAuckland City HospitalStudienpraxis UrologieCentre Eugène MarquisGeneral University Hospital Gregorio Mara?ónH?pital Européen Georges Pompidou University of ParisGustave RoussySaarland University Medical CenterGU Research Network-Urology Cancer CenterVall d'Hebron Institute of OncologyCross Cancer Institute and University of AlbertaParacelsus Medical UniversityMacquarie UniversityUniversity of WollongongMerck & Co. Inc.The Institute of Cancer Research and the Royal Marsden;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类泌尿科学（泌尿生殖系疾病）;
关键词

相似文献

外文文献

1. Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study [J] . Yu E.Y., Piulats J.M., Gravis G.Fong P.C.C.Todenhofer T.Laguerre B.Arranz J.A.Oudard S.Massard C.Heinzelbecker J.Nordquist L.T.Carles J.Kolinsky M.P.Augustin M.Gurney H.Tafreshi A.Li X.T.Qiu P.Poehlein C.H.Schloss C.de Bono J.S. European urology . 2023,第1期

机译：Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study
2. Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study [J] . Yu E.Y., Kolinsky M.P., Berry W.R.Retz M.Mourey L.Piulats J.M.Appleman L.J.Romano E.Gravis G.Gurney H.Bogemann M.Emmenegger U.Joshua A.M.Linch M.Sridhar S.Conter H.J.Laguerre B.Massard C.Li X.T.Schloss C.Poehlein C.H.de Bono J.S. European urology . 2022,第1期

机译：Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study

Corrigendum to “Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study” Eur Urol 83 (2023) 15–26, (S0302283822025544), (10.1016/j.eururo.2022.08.005)

摘要

著录项

相似文献

相关主题

期刊订阅